Robeco Institutional Asset Management B.V. Has $182.92 Million Stake in Dr. Reddy’s Laboratories Ltd $RDY

by · The Markets Daily

Robeco Institutional Asset Management B.V. increased its position in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Free Report) by 7.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,084,506 shares of the company’s stock after purchasing an additional 921,078 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 1.57% of Dr. Reddy’s Laboratories worth $182,921,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in RDY. Westside Investment Management Inc. acquired a new position in Dr. Reddy’s Laboratories in the 2nd quarter valued at $35,000. EverSource Wealth Advisors LLC boosted its position in shares of Dr. Reddy’s Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after acquiring an additional 1,294 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Dr. Reddy’s Laboratories by 217.4% in the third quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company’s stock valued at $50,000 after acquiring an additional 2,444 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Dr. Reddy’s Laboratories in the second quarter valued at about $67,000. Finally, Allworth Financial LP increased its position in Dr. Reddy’s Laboratories by 37.8% during the second quarter. Allworth Financial LP now owns 4,827 shares of the company’s stock worth $73,000 after acquiring an additional 1,323 shares during the period. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $13.82 on Tuesday. The company has a market cap of $11.53 billion, a price-to-earnings ratio of 17.06, a PEG ratio of 6.55 and a beta of 0.37. Dr. Reddy’s Laboratories Ltd has a fifty-two week low of $12.26 and a fifty-two week high of $16.17. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.35 and a current ratio of 1.85. The stock has a fifty day moving average price of $13.91 and a 200-day moving average price of $14.26.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last posted its quarterly earnings results on Friday, October 24th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.13% and a net margin of 17.14%.The business had revenue of $993.72 million during the quarter, compared to the consensus estimate of $944.26 million. As a group, equities analysts anticipate that Dr. Reddy’s Laboratories Ltd will post 0.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $16.90.

Read Our Latest Stock Report on RDY

Dr. Reddy’s Laboratories Profile

(Free Report)

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.

Further Reading

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Free Report).